References

10.1002/cpt.70148

10.1002/cpt.70148 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Reducing safety‐related drug attrition: the use of in vitro pharmacological profiling

10.1038/nrd3845 · 2012 · External reference

The state of the art in secondary pharmacology and its impact on the safety of new medicines

10.1038/s41573-024-00942-3 · 2024 · External reference

Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels

10.1038/s41573-025-01184-7 · 2025 · External reference

Secondary pharmacology data to assess potential off‐target activity of new drugs: a regulatory perspective

10.1038/nrd3845-c1 · 2015 · External reference

A practical guide to secondary pharmacology in drug discovery

10.1016/j.vascn.2020.106869 · 2020 · External reference

Unresolved reference

External reference

The human and non‐human primate developmental GTEx projects

10.1038/s41586-024-08244-9 · 2025 · External reference

Genetic variation across and within individuals

10.1038/s41576-024-00709-x · 2024 · External reference

Unresolved reference

External reference

A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development

10.1016/j.medj.2022.06.001 · 2022 · External reference

Predicting clinical outcomes from off‐target receptor interactions using secondary intelligence

10.1016/j.vascn.2024.107570 · 2025 · External reference

A comparison of pediatric and adult safety studies for antipsychotic and antidepressant drugs submitted to the United States Food and Drug Administration

10.1016/j.jpeds.2018.12.033 · 2019 · External reference

The rising misuse of pharmacovigilance reporting systems: a threat to evidence‐based medicine

10.1002/cpt.70180 · 2026 · External reference

Analysis of secondary pharmacology assays received by the US Food and Drug Administration

10.1016/j.vascn.2022.107205 · 2022 · External reference

From guideline to practice: three years of ICH S11 insights and recommendations

10.3389/fmed.2025.1537001 · 2025 · External reference

Pediatric developmental drug toxicity: description of juvenile animal studies in US FDA prescribing information and assessing the need for new approach methodologies

10.1002/jcph.70030 · 2025 · External reference

Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment

10.1016/j.drudis.2025.104328 · 2025 · External reference

Multiorgan microphysiological Systems for Drug Development: strategies, advances, and challenges

10.1002/adhm.201701000 · 2018 · External reference

Biology‐inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare

2025 · External reference

Multi‐organ toxicity demonstration in a functional human in vitro system composed of four organs

10.1038/srep20030 · 2016 · External reference

Investigation of the effect of hepatic metabolism on off‐target cardiotoxicity in a multi‐organ human‐on‐a‐chip system

10.1016/j.biomaterials.2018.07.062 · 2018 · External reference

On the potential of in vitro organ‐chip models to define temporal pharmacokinetic‐pharmacodynamic relationships

10.1038/s41598-019-45656-4 · 2019 · External reference

A functional hiPSC‐cortical neuron differentiation and maturation model and its application to neurological disorders

10.1016/j.stemcr.2021.11.009 · 2022 · External reference

Maternal and pediatric precision in therapeutic knowledge portal (MPRINT‐KP): landscape analysis of pharmacology research in maternal and pediatric patient populations

10.1002/phar.70096 · 2026 · External reference

Identifying pediatric drug safety knowledge gaps: an integrated approach leveraging real‐world data, a biomedical Knowledge Base, and Postmarketing surveillance data

10.1002/phar.70061 · 2025 · External reference

Quantitative system pharmacology as a legitimate approach to examine extrapolation strategies used to support pediatric drug development

10.1002/psp4.12801 · 2022 · External reference

Landscape of regulatory quantitative systems pharmacology submissions to the US Food and Drug Administration: an update report

10.1002/psp4.13208 · 2024 · External reference

Systems pharmacology to predict drug toxicity: integration across levels of biological organization

10.1146/annurev-pharmtox-011112-140248 · 2013 · External reference

Quantitative systems toxicology and drug development: the DILIsym experience

10.1007/978-1-0716-2265-0_9 · 2022 · External reference

Model‐informed drug development: current US regulatory practice and future considerations

10.1002/cpt.1363 · 2019 · External reference

Population physiologically‐based pharmacokinetic modeling to determine ontogeny: a quantitative clinical pharmacology example in pediatric rare disease

10.1002/psp4.70174 · 2026 · External reference

Membrane transporters in drug development and as determinants of precision medicine

10.1038/s41573-023-00877-1 · 2024 · External reference

Quantitative proteomics in translational absorption, distribution, metabolism, and excretion and precision medicine

10.1124/pharmrev.121.000449 · 2022 · External reference

From endogenous compounds as biomarkers to plasma‐derived nanovesicles as liquid biopsy; has the Golden age of translational pharmacokinetics‐absorption, distribution, metabolism, excretion‐drug‐drug interaction science finally arrived?

10.1002/cpt.1328 · 2019 · External reference

From discovery to translation: endogenous substrates of OAT1 and OAT3 as clinical biomarkers for renal secretory function

10.1002/cpt.3719 · 2025 · External reference

Developmental expression of drug transporters and conjugating enzymes involved in enterohepatic recycling: implication for pediatric drug dosing

10.1002/cpt.3409 · 2024 · External reference

A novel human stem cell‐based biomarker assay for in vitro assessment of developmental toxicity

10.1002/bdr2.2001 · 2022 · External reference

Use of quantitative in vitro to in vivo extrapolation (QIVIVE) for the assessment of non‐combustible next‐generation product aerosols

10.3389/ftox.2024.1373325 · 2024 · External reference

Development and application of a life‐stage physiologically based pharmacokinetic (PBPK) model to the assessment of internal dose of pyrethroids in humans

10.1093/toxsci/kfz211 · 2020 · External reference

Physiologically‐based pharmacokinetic modeling to support pediatric clinical development: an IQ working group perspective on the current status and challenges

10.1002/psp4.70141 · 2026 · External reference

In vitro and computational approaches to predict developmental toxicity: integrating PBPK models with cell‐based assays

10.1016/j.taap.2025.117435 · 2025 · External reference

In vitro to in vivo extrapolation from 3D hiPSC‐derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next‐generation arrhythmia risk assessment

10.1093/toxsci/kfae079 · 2024 · External reference

Animal‐free assessment of developmental toxicity: combining PBPK modeling with the ReproTracker assay

10.1016/j.tox.2023.153684 · 2023 · External reference

10.1002/bcp.70393

10.1002/bcp.70393 · External reference

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

10.1038/clpt.2010.298 · 2011 · External reference

Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 submissions to the US FDA's Office of Clinical Pharmacology

2020 · External reference

Translation of a human‐based malaria‐on‐a‐Chip phenotypic disease model for in vivo applications

10.1002/advs.202505206 · 2025 · External reference